Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
On Tuesday, Defiance ETFs introduced (NASDAQ:NVOX), the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO).
周二，Defiance ETF推出了（纳斯达克股票代码：NVOX），这是第一只专注于丹麦制药巨头诺和诺德A/S（纽约证券交易所代码：NVO）的单股杠杆ETF。
The ETF offers retail investors double the daily long exposure to Novo Nordisk's stock price changes without requiring a margin account, presenting an innovative trading option.
该ETF为散户投资者提供了无需保证金账户即可获得Novo Nordisk股价变动的每日多头敞口的两倍，提供了一种创新的交易选择。
However, NVOX carries heightened risk due to its single-stock nature and does not invest directly in Novo Nordisk shares.
但是，由于其单一股票性质，NVOX的风险更高，并且不直接投资诺和诺德的股票。
Also Read: Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
另请阅读：大型制药公司推动修改特朗普领导下的拜登时代的医疗保险药品价格谈判法
Sylvia Jablonski, CEO of Defiance ETFs, emphasized the strategic importance of NVOX, highlighting Novo Nordisk's central role in the booming weight loss market.
Defiance ETF首席执行官西尔维亚·贾布隆斯基强调了NVOX的战略重要性，强调了诺和诺德在蓬勃发展的减肥市场中的核心作用。
The company produces the popular drugs Ozempic and Wegovy, which have positioned it as a key player in an industry with significant growth potential.
该公司生产流行的药物Ozempic和Wegovy，这使其成为具有巨大增长潜力的行业的关键参与者。
Novo Nordisk reported that in the third quarter of 2024, Wegovy sales reached 17.30 billion Danish kroner, up 81%, and Ozempic sales increased 26% at constant currency to 29.80 billion Danish kroner.
诺和诺德报告称，在2024年第三季度，Wegovy的销售额达到173丹麦克朗，增长了81％，而Ozempic的销售额按固定货币计算增长了26％，达到298丹麦克朗。
Jablonski described NVOX as a tool for investors looking to capitalize on this multi-trillion-dollar opportunity.
贾布隆斯基将NVOX描述为希望利用这一数万亿美元机会的投资者的工具。
Established in 2018, Defiance ETFs specializes in income and thematic investing, offering products tailored for tactical trading opportunities. Its suite of ETFs spans disruptive technologies such as artificial intelligence and quantum computing.
Defiance ETF成立于2018年，专门从事收益和主题投资，提供针对战术交易机会量身定制的产品。其ETF套件涵盖了人工智能和量子计算等颠覆性技术。
In August, Defiance ETFs introduced (NYSE:LLYX) the Defiance Daily Target 2X Long LLY ETF, which seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of Eli Lilly And Co (NYSE:LLY).
8月，Defiance ETF推出了（纽约证券交易所代码：LLYX）Defiance Daily Target 2X多头LLY ETF，其每日杠杆投资业绩是礼来公司（纽约证券交易所代码：LLY）股价每日变动百分比的两倍（200％）。
According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence of alcohol use disorder.
根据发表在《JAMA Network Open》上的研究，使用抗肥胖药物，包括胰高血糖素样肽-1受体激动剂，可降低酒精使用障碍的发病率和复发率。
Price Action: NVO stock is up 2.02% at $110.86 during the premarket session at last check Tuesday.
价格走势：在周二最后一次盘前交易中，NVO股价上涨2.02％，至110.86美元。
- PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
- PTC Therapeutics与诺华签署了价值高达约30亿美元的亨廷顿计划许可协议
Photo via Shutterstock
照片来自 Shutterstock
